Nucleome Therapeutics
PrivateLast Round
Series A
Oct 19, 2022
Total Funding Raised
$42.48M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nucleome Therapeutics is a biotechnology company that decodes the non-coding genome to discover and develop first-in-class precision medicines for inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nucleome Therapeutics Comparables
Compare Nucleome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Engine Biosciences | 81% | |
| Scenic Biotech | 77% | |
| Insitro | 76% | |
Nucleome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 19, 2022 | ||||
| Seed | Jul 17, 2019 |
Key People
Founding team and executive leadership
Nucleome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oxford Science Enterprises | Series A, Spinoff |
| M Ventures | Series A |
| British Patient Capital | Series A |
| British Patient Capital | Series A |
| Oxford Science Enterprises | Series A, Seed |
| Pfizer Ventures | Series A |
| Johnson & Johnson Innovation - JJDC, Inc. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 23, 2026
Dr. Michelle Morrow appointed as Chief Scientific Officer.
- May 27, 2025
Bhavna Hunjan appointed as new Chief Business Officer.
Nucleome Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nucleome Therapeutics's valuation, stock price, and market status.